Global Liver Cancer Treatment Market is expected to grow at a CAGR of 19.85% during the forecast period from 2018-2025

A new research report published by Fior Markets with the title Global Liver Cancer Treatment Market by Therapeutic Class (Targeted Therapy, Immunotherapy, Chemotherapy), Distribution Channel, Regions, and Global Forecast 2018-2025.

As per the report, the global liver cancer treatment market is expected to grow from USD 513.59 Million in 2017 to USD 2,186.63 Million by 2025, at a CAGR of 19.85% during the forecast period from 2018-2025. North America region emerged as the largest global market for the liver cancer treatment with a 47.58% share of the market revenue in 2017 and is anticipated to grow at the highest CAGR of 22.03% over the forecast period.

Availability of novel drugs and treatments coupled with rising awareness among the people regarding liver cancer are the factors that are driving the market growth.

DOWNLOAD FREE SAMPLE REPORT: https://www.fiormarkets.com/report-detail/386015/request-sample

Major players in the global liver cancer treatment market are Bayer AG, Bristol-Myers Squibb Company, Eisai, Exelixis, Merck, Onyx Pharmaceuticals Inc, Alnylam Pharmaceuticals, Inc, Pfizer Inc, F. Hoffmann-La Roche Ltd., Jennerex Biotherapeutics Inc, Celsion Corp, ArQule Inc, 4SC AG, Schering Pharma AG, and Merck Pharmaceuticals, and among others. Growth government funding has provided a fillip to the for the cancer treatment research activities. For instance in 2019, UC San Francisco announced its successful lab experiment to beat the aggressive liver cancer. Traditionally, targeted cancer therapies aim to disable proteins borne of cancer-causing genes. Instead, the UCSF scientists prevented these proteins, from being built in the first place.

Therapeutic class is segmented into targeted therapy, immunotherapy and chemotherapy.  As Nexavar, a targeted therapy drug is the only approved targeted therapeutic treatment that is available for the treatment of the advanced stage liver cancer, the targeted therapy segment emerged as the largest segment with a 43.86% share of revenue in 2017. Due to its increasing adoption in the combination drug treatments the immunotherapy segment is projected to grow at a CAGR of 21.63% over the forecast period. Distribution channel is divided into hospital pharmacies, retail pharmacies and online pharmacies. On account of easy availability and convenience the online pharmacy segment is projected to grow at a CAGR of 21.93% over the forecasted period.

Factors such as rising incidence of liver cancer and growing research activities for developing novel treatments coupled with increasing government funding for the cancer treatment research are driving the global liver cancer treatment market. Whereas, high research and development cost as well as stringent drug approval process and adverse side effects associated with cancer treatment medications are projected to hamper the market growth.

ACCESS FULL REPORT: https://www.fiormarkets.com/report/liver-cancer-treatment-market-by-therapeutic-class-targeted-386015.html

About the report: 
The global Liver Cancer Treatment market is analysed on the basis of value (USD Billion), volume (K Units), export (K Units), and import (K Units). All the segments have been analyzed on global, regional and country basis. The study includes an analysis of more than 30 countries for each segment. The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The study includes porter’s five forces model, attractiveness analysis, raw material analysis, and competitor position grid analysis.

Customization of the Report:
The report can be customized as per client requirements. For further queries, you can contact us on sales@fiormarkets.com or +1-201-465-4211. Our executives will be pleased to understand your requirements and offer you the best-suited reports.

Contact Us
Mark Stone
Phone: +1-201-465-4211
Email: sales@fiormarkets.com
Web: www.fiormarkets.com

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.